

02 Apr 2021 | News

QUOTED. 2 April 2021. Rebecca Kelly Slaughter.

by

The US Federal Trade Commission is trying to stop Illumina's planned acquisition of Grail, because it could reduce patients' access to multi-cancer screening tests. See what FTC chairwoman Rebecca Kelly Slaughter said about it here.

"[Multi-cancer early detection] is a game changer for cancer patients and their loved ones. If this acquisition is consummated, it would likely reduce innovation in this critical area of health care, diminish the quality of [these] tests, and make them more expensive." – Rebecca Kelly Slaughter, chairwoman, FTC

- Find out more: [US Government Opposes Proposed Illumina/Grail Merger](#)

[Click here](#) for a free trial of *Medtech Insight*